Daiichi Sankyo Company, Limited (TYO:4568)
2,559.00
+30.50 (1.21%)
Jun 9, 2026, 3:30 PM JST
Daiichi Sankyo Company Revenue
In the fiscal year ending March 31, 2026, Daiichi Sankyo Company had annual revenue of 2.12T JPY with 12.55% growth. Daiichi Sankyo Company had revenue of 589.59B in the quarter ending March 31, 2026, with 13.67% growth.
Revenue
2.12T
Revenue Growth
+12.55%
P/S Ratio
2.19
Revenue / Employee
107.41M
Employees
19,765
Market Cap
4.66T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.12T | 236.79B | 12.55% |
| Mar 31, 2025 | 1.89T | 284.57B | 17.77% |
| Mar 31, 2024 | 1.60T | 323.21B | 25.28% |
| Mar 31, 2023 | 1.28T | 233.59B | 22.36% |
| Mar 31, 2022 | 1.04T | 82.38B | 8.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.52T |
| Astellas Pharma | 2.14T |
| Chugai Pharmaceutical | 1.29T |
| Ono Pharmaceutical | 515.79B |
| Kyowa Kirin | 510.57B |
| Santen Pharmaceutical | 291.62B |
| JCR Pharmaceuticals | 40.32B |
| Perseus Proteomics | 135.00M |
Daiichi Sankyo Company News
- 12 days ago - Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO - Business Wire
- 13 days ago - Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026 - Business Wire
- 17 days ago - FDA Approves AstraZeneca And Daiichi's Datroway For Treating Metastatic Breast Cancer - Nasdaq
- 21 days ago - Full Year 2026 Daiichi Sankyo Co Ltd Earnings Presentation Transcript - GuruFocus
- 22 days ago - AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA Approval In Two Early Breast Cancer Indications - Nasdaq
- 22 days ago - AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings - Nasdaq
- 4 weeks ago - Daiichi Sankyo Company Earnings Call Transcript: Q4 2026 - Transcripts
- 4 weeks ago - Daiichi Sankyo Company Quarterly report: Q4 2026 - Filings